Statins and congestive heart failure

Martin, Jennifer (2008) Statins and congestive heart failure. Current Atherosclerosis Reports, 10 5: 369-376. doi:10.1007/s11883-008-0058-3


Author Martin, Jennifer
Title Statins and congestive heart failure
Journal name Current Atherosclerosis Reports   Check publisher's open access policy
ISSN 1523-3804
1534-6242
Publication date 2008-10-01
Year available 2008
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1007/s11883-008-0058-3
Open Access Status
Volume 10
Issue 5
Start page 369
End page 376
Total pages 8
Place of publication Philadelphia, PA, U.S.A.
Publisher Current Medicine Group
Language eng
Subject 1103 Clinical Sciences
Abstract Despite many post hoc analyses of cardiovascular databases in recent years suggesting a benefit of statins in the prevention and treatment of congestive heart failure (HF), a prospective study of statin therapy on two clinically relevant end points-HF morbidity and survival-had not been reported until 2007. However, a large-scale prospective trial, Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA), has just reported its primary results. These results somewhat surprisingly show no survival benefit in a group of patients with ischemic systolic HF given low-dose rosuvastatin. In addition to this uncertainty generated by the results of CORONA, there remains additional uncertainty in the existing, predominantly retrospective data on statins because of the potential bias in study designs, use of post hoc subgroup analyses, and lack of mechanistic data. This review critically evaluates the recent literature in this area.
Formatted abstract
Despite many post hoc analyses of cardiovascular databases in recent years suggesting a benefit of statins in the prevention and treatment of congestive heart failure (HF), a prospective study of statin therapy on two clinically relevant end points—HF morbidity and survival—had not been reported until 2007. However, a large-scale prospective trial, Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA), has just reported its primary results. These results somewhat surprisingly show no survival benefit in a group of patients with ischemic systolic HF given low-dose rosuvastatin. In addition to this uncertainty generated by the results of CORONA, there remains additional uncertainty in the existing, predominantly retrospective data on statins because of the potential bias in study designs, use of post hoc subgroup analyses, and lack of mechanistic data. This review critically evaluates the recent literature in this area.
Copyright © 2008 by Current Medicine Group LLC
Keyword CoA reductase inhibitors
Endothelial nitric oxide
Smooth muscle cells
Acute myocardial infarction
Induced cardiac hypertrophy
Serum cholesterol levels
Low density lipoprotein
C reactive protein
Elderly patients
Lower mortality
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Excellence in Research Australia (ERA) - Collection
School of Medicine Publications
UQ Diamantina Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 31 Mar 2009, 23:20:40 EST by Kylie Hengst on behalf of UQ Diamantina Institute